Your browser doesn't support javascript.
loading
Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM).
Mora-Rodríguez, José María; Sánchez, Belén G; Bort, Alicia; Díaz-Yuste, Alba; Ballester-González, Rubén; Arrieta, Francisco; Sebastián-Martín, Alba; Díaz-Laviada, Inés.
Affiliation
  • Mora-Rodríguez JM; Department of Systems Biology, School of Medicine and Health Sciences, Alcalá University, Alcalá de Henares, Spain; Health Research Institute of Castilla-La Mancha (IDISCAM), Spain. Electronic address: josem.mora@uah.es.
  • Sánchez BG; Department of Systems Biology, School of Medicine and Health Sciences, Alcalá University, Alcalá de Henares, Spain; Health Research Institute of Castilla-La Mancha (IDISCAM), Spain. Electronic address: belen.sanchezg@uah.es.
  • Bort A; Department of Systems Biology, School of Medicine and Health Sciences, Alcalá University, Alcalá de Henares, Spain; Health Research Institute of Castilla-La Mancha (IDISCAM), Spain. Electronic address: alicia.bort@uah.es.
  • Díaz-Yuste A; Department of Systems Biology, School of Medicine and Health Sciences, Alcalá University, Alcalá de Henares, Spain; Health Research Institute of Castilla-La Mancha (IDISCAM), Spain. Electronic address: alba.diazy@edu.uah.es.
  • Ballester-González R; Immunology Service, Ramón y Cajal Hospital, Ramón y Cajal Institute for Health Research (IRYCIS), Madrid, Spain. Electronic address: ruben.ballester@salud.madrid.org.
  • Arrieta F; Endocrinology and Nutrition Service, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain. Electronic address: farrietab.hrc@salud.madrid.org.
  • Sebastián-Martín A; Department of Systems Biology, School of Medicine and Health Sciences, Alcalá University, Alcalá de Henares, Spain; Health Research Institute of Castilla-La Mancha (IDISCAM), Spain. Electronic address: alba.sebastian@uah.es.
  • Díaz-Laviada I; Department of Systems Biology, School of Medicine and Health Sciences, Alcalá University, Alcalá de Henares, Spain; Health Research Institute of Castilla-La Mancha (IDISCAM), Spain; Chemical Research Institute "Andrés M. del Río" (IQAR), Alcalá de Henares, Spain. Electronic address: ines.diazlaviada
Life Sci ; 336: 122292, 2024 Jan 01.
Article in En | MEDLINE | ID: mdl-38030058
ABSTRACT

AIMS:

Dipeptidyl peptidase 4 (DPP4) has been proposed as a coreceptor for SARS-CoV-2 cellular entry. Considering that type 2 diabetes mellitus (T2DM) has been identified as the most important risk factor for SARS-CoV-2, and that gliptins (DPP4 inhibitors) are a prescribed diabetic treatment, this study aims to unravel the impact of DPP4 in the intersection of T2DM/COVID-19. MATERIALS AND

METHODS:

We analyzed 189 serum human samples, divided into six clinical groups (controls, T2DM, T2DM + gliptins, COVID-19, COVID-19 + T2DM, and COVID-19 + T2DM + gliptins), measuring DPP4 protein concentration and activity by Western blot, ELISA, and commercial activity kits. The obtained results were verified in Huh-7 cellular models. KEY

FINDINGS:

Both DPP4 concentration and activity were decreased in COVID-19 patients, and as in T2DM patients, compared to controls. Despite these lower levels, the ratio of DPP4 activity/concentration in COVID-19 sera was the highest (0.782 ± 0.289 µU/ng vs. 0.547 ± 0.050 µU/ng in controls, p < 0.0001), suggesting a compensating mechanism in these patients. Supernatants of Huh-7 cells incubated with COVID-19 serum showed a consistent and significantly lower DPP4 concentration and activity. Furthermore, COVID-19 + T2DM + gliptins patients showed a higher serum DPP4 concentration and activity than T2DM + gliptin subjects (p < 0.05), indicating that sera from COVID-19 convalescents interfere with gliptins.

SIGNIFICANCE:

Either SARS-CoV-2 or some metabolites present in the sera of COVID-19-convalescent patients interact with soluble DPP4 or even gliptins themselves since the inhibitory effect of gliptins on DPP4 activity is being prevented. The interactions between DPP4, gliptins, and SARS-CoV-2 should be further elucidated to reveal the mechanism of action for these interesting observations.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / COVID-19 Limits: Humans Language: En Journal: Life Sci Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / COVID-19 Limits: Humans Language: En Journal: Life Sci Year: 2024 Document type: Article